Research and Markets has announced the addition of the "Acute Myocardial Infarction Pipeline Highlights - 2017" drug pipelines to their offering.

This report, Acute Myocardial Infarction Pipeline Highlights - 2017, provides most up-to-date information on key pipeline products in the global Acute Myocardial Infarction market. It covers emerging therapies for Acute Myocardial Infarction in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Acute Myocardial Infarction pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Acute Myocardial Infarction pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Acute Myocardial Infarction pipeline products by the company.

Short-term Launch Highlights:

Find out which Acute Myocardial Infarction pipeline products will be launched in the US and Ex-US till 2020.

Summary:

- Acute Myocardial Infarction phase 3 clinical trial pipeline products

- Acute Myocardial Infarction phase 2 clinical trial pipeline products

- Acute Myocardial Infarction phase 1 clinical trial pipeline products

- Acute Myocardial Infarction preclinical research pipeline products

- Acute Myocardial Infarction discovery stage pipeline products

- Acute Myocardial Infarction pipeline products short-term launch highlights

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/3dfg9w/acute_myocardial